COVID-19
REACT Observational Study of COVID-19
Year Started: 2020
SARS-CoV-2 has emerged as a global pandemic in 2020. There are no effective treatments and an effective vaccine has not been developed. Whilst many patients recover without need for hospitalisation, a small proportion go on to develop severe disease. A better understanding of the natural history of this disease will facilitate improved clinical management with the potential to identify options for intervention. This proposal is for the formal collection of characterisation data for patients tested for and/or admitted with a confirmed diagnosis of SARS-CoV-2 infection. This study responds to the need for a clear understanding of the natural history of this novel, emerging pandemic. Specifically phenotypic characterisation may enable application of personalised medical approaches, based on clinical course, to aid earlier identification of patients at risk of severe disease, and facilitate identification of potential targets for novel treatments. The collection and characterisation of these patients reflects a strong partnership between NHS and academic critical care and respiratory medicine in Southampton that acts as both a secondary and tertiary centre, with support from the digital experimental cancer medicine team at the University of Manchester.
- Access:
- Access restricted at present
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Commercial restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Pathology records | > 6 months |
Physiological/biochemical measurements | > 6 months |
Quality indicators | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Male
Adolescent (12 - 18 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | Not applicable | 51 - 75% | ||
Plasma | -60°C to -85°C | Not applicable | 11 - 25% | ||
Whole blood | -60°C to -85°C | Not applicable | 0 - 10% | ||
Swab | -60°C to -85°C | Not applicable | 0 - 10% | ||
Saliva | -60°C to -85°C | Not applicable | 11 - 25% | ||
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 0 - 10% | ||
Urine | -60°C to -85°C | Not applicable | 0 - 10% | ||
RNA | -60°C to -85°C | Not applicable | 0 - 10% |
Female
Adolescent (12 - 18 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | Not applicable | 51 - 75% | ||
Plasma | -60°C to -85°C | Not applicable | 11 - 25% | ||
Whole blood | -60°C to -85°C | Not applicable | 0 - 10% | ||
Swab | -60°C to -85°C | Not applicable | 0 - 10% | ||
Saliva | -60°C to -85°C | Not applicable | 11 - 25% | ||
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 0 - 10% | ||
Urine | -60°C to -85°C | Not applicable | 0 - 10% | ||
RNA | -60°C to -85°C | Not applicable | 0 - 10% |